DAHANCA 19: The Importance of the EGFr-inhibitor Zalutumumab for the Outcome After Curative Radiotherapy for HNSCC

This study is currently recruiting participants.

Study NCT00496652 Information provided by Danish Head and Neck Cancer Group

First Received: July 3, 2007 Last Updated: January 3, 2012 History of Changes

No Study Results Posted on ClinicalTrials.gov for this Study

Study Status:	This study is currently recruiting participants.
Estimated Study Completion Date:	November 2016
Estimated Primary Completion Date:	May 2012 (Final data collection date for primary outcome measure)